Cinctive Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-3,305
Closed -$995K – 409
2026
Q2
$995K Buy
+3,305
New +$997K 0.04% 326
2025
Q3
– Sell
-22,868
Closed -$7.46M – 397
2025
Q2
$7.46M Sell
22,868
-1,994
-8% -$552K 0.39% 82
2025
Q1
$6.71M Buy
24,862
+6,622
+36% +$1.7M 0.51% 59
2024
Q4
$4.29M Buy
+18,240
New +$4.8M 0.22% 150
2024
Q3
– Sell
-6,781
Closed -$1.65M – 376
2024
Q2
$1.65M Sell
6,781
-203
-3% -$32K 0.08% 267
2024
Q1
$1.04M Buy
+6,984
New +$1.17M 0.05% 283
2022
Q1
– Sell
-6,990
Closed -$1.18M – 503
2021
Q4
$1.18M Buy
+6,990
New +$1.3M 0.05% 382
2021
Q1
– Sell
-27,721
Closed -$3.6M – 403
2020
Q4
$3.6M Buy
+27,721
New +$3.7M 0.29% 145

Other funds holding ALNY

Cinctive Capital Management's ALNY Position: Q3 2026 in Review

Cinctive Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2026, closing a stake of 3,305 shares — an estimated $995K sold.

Cinctive Capital Management first reported a position in ALNY in Q4 2020 and held it in 8 quarters. The position peaked at $7.46M in Q2 2025. 720 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Cinctive Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • Cinctive Capital Management sold 3,305 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $995K.
  • Cinctive Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2020 and held it in 8 quarters.
  • Cinctive Capital Management's Alnylam Pharmaceuticals position peaked at $7.46M in Q2 2025.
  • 720 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Cinctive Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.